OAM
BTAI icon

Oxford Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Oxford Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,201
Closed -$281K – 368
2019
Q4 		$281K Buy
+1,201
New +$121K 0.01% 1455

Other funds holding BTAI

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oxford Asset Management's BTAI Position: Q1 2020 in Review

Oxford Asset Management sold out of BioXcel Therapeutics (BTAI) in Q1 2020, closing a stake of 1,201 shares — an estimated $281K sold.

Oxford Asset Management first reported a position in BTAI in Q4 2019 and held it in 1 quarter. The position peaked at $281K in Q4 2019. 70 funds tracked by Wall St. Rank hold BTAI as of Q1 2020.

  • Oxford Asset Management reported no remaining BioXcel Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 1,201 BioXcel Therapeutics shares in Q1 2020, an estimated $281K.
  • Oxford Asset Management first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 1 quarter.
  • Oxford Asset Management's BioXcel Therapeutics position peaked at $281K in Q4 2019.
  • 70 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.